Paper42423955
Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.
Chen H and 4 others. Int Urol Nephrol, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype. Papers, record 42423955. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42423955
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26546618 | Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26546618 | PubMed |
| 2 | 33112397 | Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. | JAMA Netw Open | 2020 | https://conductscience.org/library/papers/33112397 | PubMed |
| 3 | 33904759 | Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination. | J Urol | 2021 | https://conductscience.org/library/papers/33904759 | PubMed |
| 4 | 33690902 | Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. | Cancer | 2021 | https://conductscience.org/library/papers/33690902 | PubMed |
| 5 | 32856010 | Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. | JCO Precis Oncol | 2020 | https://conductscience.org/library/papers/32856010 | PubMed |
| 6 | 31515154 | Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31515154 | PubMed |
| 7 | 37722977 | Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis. | Eur Urol Oncol | 2024 | https://conductscience.org/library/papers/37722977 | PubMed |
| 8 | 40413129 | Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency. | Eur Urol Oncol | 2026 | https://conductscience.org/library/papers/40413129 | PubMed |
| 9 | 37193610 | Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. | Clin Genitourin Cancer | 2023 | https://conductscience.org/library/papers/37193610 | PubMed |
| 10 | 37648316 | Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. | Anticancer Res | 2023 | https://conductscience.org/library/papers/37648316 | PubMed |
| 11 | 31525487 | Clinical features of neuroendocrine prostate cancer. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/31525487 | PubMed |
| 12 | 30713600 | Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. | Oncotarget | 2019 | https://conductscience.org/library/papers/30713600 | PubMed |
| 13 | 35347041 | Treatment Outcomes in Neuroendocrine Prostate Cancer. | Anticancer Res | 2022 | https://conductscience.org/library/papers/35347041 | PubMed |
| 14 | 33339136 | Neuroendocrine and Aggressive-Variant Prostate Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33339136 | PubMed |
| 15 | 36200788 | The Value of Phenotypic Precision Medicine in Prostate Cancer. | Oncologist | 2023 | https://conductscience.org/library/papers/36200788 | PubMed |
| 16 | 34948423 | Combined In Silico, Ex Vivo, and In Vivo Assessment of L-17, a Thiadiazine Derivative with Putative Neuro- and Cardioprotective and Antidepressant Effects. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34948423 | PubMed |
| 17 | 26724258 | Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2016 | https://conductscience.org/library/papers/26724258 | PubMed |
| 18 | 28608931 | The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. | Cancer | 2017 | https://conductscience.org/library/papers/28608931 | PubMed |
| 19 | 30340782 | Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. | Eur Urol | 2019 | https://conductscience.org/library/papers/30340782 | PubMed |
| 20 | 38484203 | Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38484203 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42545565 | Comment on "Deficit accumulation frailty and risk of incident chronic kidney disease: a prospective analysis of the UK Biobank and CHARLS cohorts". | Int Urol Nephrol | 2026 | https://conductscience.org/library/papers/42545565 | PubMed |
| 42479376 | Frailty and chronic kidney disease: beyond risk prediction toward frailty-informed CKD classification. | Int Urol Nephrol | 2026 | https://conductscience.org/library/papers/42479376 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATM | 472 | PubTator's text mining | https://conductscience.org/library/genes/472 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| CDK12 | 51755 | PubTator's text mining | https://conductscience.org/library/genes/51755 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42423955
GET https://conductscience.org/api/papers/v1/42423955/references?page=2